Compare ABM & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | ADPT |
|---|---|---|
| Founded | 1909 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 1994 | 2019 |
| Metric | ABM | ADPT |
|---|---|---|
| Price | $38.76 | $13.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $47.80 | $17.78 |
| AVG Volume (30 Days) | 453.0K | ★ 1.7M |
| Earning Date | 06-09-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ 102.34 | 63.89 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $8,745,900,000.00 | $276,976,000.00 |
| Revenue This Year | $5.71 | $3.98 |
| Revenue Next Year | $1.99 | $22.72 |
| P/E Ratio | $60.42 | ★ N/A |
| Revenue Growth | 4.62 | ★ 54.77 |
| 52 Week Low | $38.58 | $6.68 |
| 52 Week High | $52.94 | $20.76 |
| Indicator | ABM | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 26.44 | 30.42 |
| Support Level | N/A | $12.32 |
| Resistance Level | $46.93 | $13.45 |
| Average True Range (ATR) | 1.35 | 0.82 |
| MACD | -0.61 | -0.29 |
| Stochastic Oscillator | 10.72 | 20.71 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).